Opinion|Videos|April 22, 2024
Monitoring Patients With R/R MM for CRS and ICANS
Author(s)Caitlin Costello, MD, Matthew James Pianko, MD
Matthew Pianko, MD, explains how patients with relapsed/refractory multiple myeloma are monitored for CRS and ICANS.
Advertisement
Episodes in this series
Advertisement
Related to this article
Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.
Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.
Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.
Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
Perioperative Pembrolizumab Plus Chemo Does Not Significantly Improve EFS in MIBC
2
Adjuvant Ribociclib Improves OS at 6 Years in HR+/HER2- Early Breast Cancer
3
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
4
Extended Letrozole Sustains DFS Benefit at 15 Years in HR+ Breast Cancer
5